TY - JOUR
T1 - Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection
AU - Cacopardo, Bruno
AU - Camma, Calogero
AU - Petta, Salvatore
AU - Pinzone, Marilia Rita
AU - Cappellani, Alessandro
AU - Zanghi, Antonio
AU - Nicolosi, Anna
AU - Nunnari, Giuseppe
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Although initially identified as a calcium homeostatic hormone, vitamin D is now known to have pleiotropic functions, dealing with both innate and adaptative immunity. Calcitriol mediates its biological effects by binding to the vitamin D receptor (VDR), which is expressed not only by intestine, bone and kidney but also on cell membranes of T lymphocytes, B lymphocytes, dendritic cells and macrophages. Vitamin D plays a role on the degree of liver damage in patients with chronic hepatitis C (CHC): low vitamin D levels have been associated with high hepatic necroinflammatory activity and progression of liver fibrosis. Vitamin D, in CHC patients, could also affect the response to antiviral therapy: in fact, recent studies have shown a relationship between low responsiveness to IFNbased therapy and low vitamin D serum levels. Further studies are required to better assess if vitamin D could work as a reliable noninvasive marker of liver fibrosis and whether vitamin D supplementation could be given to all CHC patients together with standard antiviral treatment, in order to improve the rate of sustained virological response (SVR).
AB - Although initially identified as a calcium homeostatic hormone, vitamin D is now known to have pleiotropic functions, dealing with both innate and adaptative immunity. Calcitriol mediates its biological effects by binding to the vitamin D receptor (VDR), which is expressed not only by intestine, bone and kidney but also on cell membranes of T lymphocytes, B lymphocytes, dendritic cells and macrophages. Vitamin D plays a role on the degree of liver damage in patients with chronic hepatitis C (CHC): low vitamin D levels have been associated with high hepatic necroinflammatory activity and progression of liver fibrosis. Vitamin D, in CHC patients, could also affect the response to antiviral therapy: in fact, recent studies have shown a relationship between low responsiveness to IFNbased therapy and low vitamin D serum levels. Further studies are required to better assess if vitamin D could work as a reliable noninvasive marker of liver fibrosis and whether vitamin D supplementation could be given to all CHC patients together with standard antiviral treatment, in order to improve the rate of sustained virological response (SVR).
KW - Chronic hepatitis C
KW - Liver fibrosis
KW - Pegylated Interferon
KW - Review
KW - Ribavirin
KW - Sustained Virological Response
KW - VDR
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=84860844280&partnerID=8YFLogxK
U2 - 10.2741/e458
DO - 10.2741/e458
M3 - Article
C2 - 22201953
AN - SCOPUS:84860844280
SN - 1945-0494
VL - 4 E
SP - 1276
EP - 1286
JO - Frontiers in Bioscience - Elite
JF - Frontiers in Bioscience - Elite
IS - 4
ER -